Pub Date : 2025-09-01Epub Date: 2025-09-08DOI: 10.4174/astr.2025.109.3.123
Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Ki, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
Compared with other treatments, surgical resection is an effective treatment method with the lowest local recurrence rate and the highest survival rate for hepatocellular carcinoma (HCC). To achieve excellent results after surgical treatment, it is essential to carefully select patients who are suitable for hepatic resection and minimize postoperative complications and liver function decline through standardized surgical methods and pre- and postoperative management. However, domestic and international treatment guidelines only broadly recommend the application of hepatic resection for HCC with a single tumor and good liver function. Hence, practical treatment guidelines are required that can be standardized and used according to the varying clinical environments, including indications for hepatic resection, preoperative evaluation, basic principles of hepatic resection, minimally invasive hepatic resection, pre- and postoperative patient management, surgical treatment considerations in specific infection situations, and follow-up after surgical resection. Accordingly, an expert group from the Korean Liver Cancer Association Research Committee has developed practical recommendations based on expert consensus regarding the surgical treatment of HCC through a Delphi study.
{"title":"Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association.","authors":"Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Ki, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim","doi":"10.4174/astr.2025.109.3.123","DOIUrl":"10.4174/astr.2025.109.3.123","url":null,"abstract":"<p><p>Compared with other treatments, surgical resection is an effective treatment method with the lowest local recurrence rate and the highest survival rate for hepatocellular carcinoma (HCC). To achieve excellent results after surgical treatment, it is essential to carefully select patients who are suitable for hepatic resection and minimize postoperative complications and liver function decline through standardized surgical methods and pre- and postoperative management. However, domestic and international treatment guidelines only broadly recommend the application of hepatic resection for HCC with a single tumor and good liver function. Hence, practical treatment guidelines are required that can be standardized and used according to the varying clinical environments, including indications for hepatic resection, preoperative evaluation, basic principles of hepatic resection, minimally invasive hepatic resection, pre- and postoperative patient management, surgical treatment considerations in specific infection situations, and follow-up after surgical resection. Accordingly, an expert group from the Korean Liver Cancer Association Research Committee has developed practical recommendations based on expert consensus regarding the surgical treatment of HCC through a Delphi study.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 3","pages":"123-143"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-30DOI: 10.4174/astr.2025.109.2.81
Hayemin Lee, Mi Ryeong Park, Junhyun Lee
Purpose: According to the guidelines of the Japanese Gastric Cancer Association, endoscopic submucosal dissection (ESD) is safe for gastric cancer (GC) patients with absolute indications because the possibility of lymph node metastasis (LNM) is 0%. The aim of this study was to reveal the exact proportion of Korean GC patients with LNM whose pathological examination revealed indications for ESD.
Methods: Data were extracted from the '2019 Korean Nationwide Retrospective Database' managed by the Korean Gastric Cancer Association. Among the 14,076 patients, 4,220 patients with stage T1a cancer after radical gastrectomy were enrolled. Pathological examination was performed to ascertain the tumor diameter, depth of invasion, tumor differentiation, presence of lymphovascular/perineural invasion, and presence of ulceration.
Results: The proportion of patients with LNM and absolute indications was 2.4% (49 of 2,012). The 95% confidence interval for the proportion of patients with LNM was greater than 1.0% across all subgroups in terms of absolute indications. According to the multivariate regression model, the risk factors for LNM were lymphovascular invasion (odds ratio [OR], 7.56), perineural invasion (OR, 3.02), a tumor size >2 cm (OR, 2.37), undifferentiated tumors (OR, 2.30), and ulceration (OR, 1.66).
Conclusion: Compared with Japanese studies, this study revealed a relatively high proportion of Korean GC patients with LNM and absolute indications for ESD. The Japanese guidelines for ESD could be applied to Korean GC patients if done carefully.
{"title":"Can the Japanese guidelines for endoscopic submucosal dissection be safely applied to Korean gastric cancer patients? A multicenter retrospective study based on the Korean Gastric Cancer Association nationwide survey.","authors":"Hayemin Lee, Mi Ryeong Park, Junhyun Lee","doi":"10.4174/astr.2025.109.2.81","DOIUrl":"10.4174/astr.2025.109.2.81","url":null,"abstract":"<p><strong>Purpose: </strong>According to the guidelines of the Japanese Gastric Cancer Association, endoscopic submucosal dissection (ESD) is safe for gastric cancer (GC) patients with absolute indications because the possibility of lymph node metastasis (LNM) is 0%. The aim of this study was to reveal the exact proportion of Korean GC patients with LNM whose pathological examination revealed indications for ESD.</p><p><strong>Methods: </strong>Data were extracted from the '2019 Korean Nationwide Retrospective Database' managed by the Korean Gastric Cancer Association. Among the 14,076 patients, 4,220 patients with stage T1a cancer after radical gastrectomy were enrolled. Pathological examination was performed to ascertain the tumor diameter, depth of invasion, tumor differentiation, presence of lymphovascular/perineural invasion, and presence of ulceration.</p><p><strong>Results: </strong>The proportion of patients with LNM and absolute indications was 2.4% (49 of 2,012). The 95% confidence interval for the proportion of patients with LNM was greater than 1.0% across all subgroups in terms of absolute indications. According to the multivariate regression model, the risk factors for LNM were lymphovascular invasion (odds ratio [OR], 7.56), perineural invasion (OR, 3.02), a tumor size >2 cm (OR, 2.37), undifferentiated tumors (OR, 2.30), and ulceration (OR, 1.66).</p><p><strong>Conclusion: </strong>Compared with Japanese studies, this study revealed a relatively high proportion of Korean GC patients with LNM and absolute indications for ESD. The Japanese guidelines for ESD could be applied to Korean GC patients if done carefully.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"81-88"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-30DOI: 10.4174/astr.2025.109.2.61
Ha Eun Kim, Hye-Sol Jung, Youngmin Han, Yoon Soo Chae, Won-Gun Yun, Young Jae Cho, Wooil Kwon, Joon Seong Park, Jin-Young Jang
Purpose: With neoadjuvant treatment (NAT) broadening the surgical indication for advanced pancreatic cancer, the growing use of robotic platforms in pancreaticoduodenectomy (PD) necessitates the evaluation of its feasibility in advanced pancreatic cancer patients who have undergone NAT.
Methods: We compared clinicopathological outcomes of advanced pancreatic cancer patients who received either robot-assisted or open PD after NAT at a tertiary hospital from 2015 to 2023. Propensity score matching was performed based on age, sex, and TNM staging.
Results: Among 223 patients who received conversion surgery after NAT, 42 open PD and 14 robot-assisted PD patients were matched in a 3:1 ratio. There was a trend of shorter hospital stays (11.4 days vs. 9.8 days, P = 0.218) and less severe postoperative complications (21.4% vs. 7.1%; P = 0.227) in the robot-assisted PD group. Lymph node (LN) yield, LN metastasis rate, and R0 resection rates were similar between the 2 groups. The overall (OS) and disease-free survival (DFS) rates between the 2 groups were comparable (5-year OS rate: 55.7% vs. 72.7%, P = 0.264; 5-year DFS rate: 54.4% vs. 58.4%, P = 0.759).
Conclusion: Robot-assisted PD offers comparable short-term and long-term outcomes to open PD, even in patients undergoing conversion surgery after NAT.
目的:随着新辅助治疗(NAT)拓宽了晚期胰腺癌的手术指征,机器人平台在胰十二指肠切除术(PD)中的应用越来越多,有必要对其在接受过NAT的晚期胰腺癌患者中的可行性进行评估。方法:我们比较2015年至2023年在某三级医院接受NAT后机器人辅助或开放式PD的晚期胰腺癌患者的临床病理结果。根据年龄、性别和TNM分期进行倾向评分匹配。结果:223例NAT术后转换手术患者中,开放PD 42例,机器人辅助PD 14例,比例为3:1。住院时间缩短(11.4天比9.8天,P = 0.218),术后并发症减少(21.4%比7.1%;P = 0.227)。两组间淋巴结(LN)产出率、淋巴结转移率、R0切除率相似。两组的总生存率(OS)和无病生存率(DFS)具有可比性(5年生存率:55.7% vs. 72.7%, P = 0.264;5年DFS率:54.4% vs. 58.4%, P = 0.759)。结论:机器人辅助PD的短期和长期效果与开放式PD相当,即使在NAT后接受转换手术的患者中也是如此。
{"title":"Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic ductal adenocarcinoma: a retrospective propensity score-matched cohort study.","authors":"Ha Eun Kim, Hye-Sol Jung, Youngmin Han, Yoon Soo Chae, Won-Gun Yun, Young Jae Cho, Wooil Kwon, Joon Seong Park, Jin-Young Jang","doi":"10.4174/astr.2025.109.2.61","DOIUrl":"10.4174/astr.2025.109.2.61","url":null,"abstract":"<p><strong>Purpose: </strong>With neoadjuvant treatment (NAT) broadening the surgical indication for advanced pancreatic cancer, the growing use of robotic platforms in pancreaticoduodenectomy (PD) necessitates the evaluation of its feasibility in advanced pancreatic cancer patients who have undergone NAT.</p><p><strong>Methods: </strong>We compared clinicopathological outcomes of advanced pancreatic cancer patients who received either robot-assisted or open PD after NAT at a tertiary hospital from 2015 to 2023. Propensity score matching was performed based on age, sex, and TNM staging.</p><p><strong>Results: </strong>Among 223 patients who received conversion surgery after NAT, 42 open PD and 14 robot-assisted PD patients were matched in a 3:1 ratio. There was a trend of shorter hospital stays (11.4 days <i>vs.</i> 9.8 days, P = 0.218) and less severe postoperative complications (21.4% <i>vs.</i> 7.1%; P = 0.227) in the robot-assisted PD group. Lymph node (LN) yield, LN metastasis rate, and R0 resection rates were similar between the 2 groups. The overall (OS) and disease-free survival (DFS) rates between the 2 groups were comparable (5-year OS rate: 55.7% <i>vs.</i> 72.7%, P = 0.264; 5-year DFS rate: 54.4% <i>vs.</i> 58.4%, P = 0.759).</p><p><strong>Conclusion: </strong>Robot-assisted PD offers comparable short-term and long-term outcomes to open PD, even in patients undergoing conversion surgery after NAT.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"61-70"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-30DOI: 10.4174/astr.2025.109.2.105
Eunji Kim, Jun Hyun Park, Ji-Young Park, Sang-Woo Lee, Jin Hyang Jung
Purpose: Oncocytic carcinoma (OCA) has been reclassified from follicular thyroid carcinoma due to its unique features. Its rarity has resulted in limited studies on differentiating OCA from oncocytic adenoma (OA). This study aimed to compare the clinicopathologic and preoperative features of OCA and OA and evaluate the effectiveness of ultrasonography and cytology.
Methods: We conducted a retrospective study involving 83 patients (23 with OCA and 60 with OA) who underwent thyroid surgery between 2011 and 2024. We reviewed clinical, ultrasonographic, cytologic, and histopathologic data to assess diagnostic performance.
Results: OCA cases had larger tumors than OA in both sonographic (4.2 ± 1.7 cm vs. 2.7 ± 1.4 cm, P < 0.001) and pathologic measurements (3.8 ± 1.7 cm vs. 2.3 ± 1.4 cm, P < 0.001). K-TIRADS (the Korean Thyroid Imaging Reporting and Data System) did not effectively distinguish OCA from OA; however, ACR TI-RADS (the American College of Radiology Thyroid Imaging Reporting and Data System) categorized more OCA cases into higher-risk groups (17.4% vs. 1.7%, P = 0.016). Trabecular formation and intranodular vascularity were more frequent in OCA (17.4% vs. 1.7%, P = 0.019; 65.2% vs. 33.3%, P = 0.049). Cytologically, 87% of OCAs were classified as follicular neoplasms compared to 20% of OAs.
Conclusion: Predicting malignancy in oncocytic neoplasms is challenging. Larger tumor size, higher ACR TI-RADS scores, and trabecular formation are potential indicators for OCA. Cytologic subcategorization within Bethesda IV suggests follicular neoplasms carry a higher malignancy risk than oncocytic neoplasms. Multicenter studies are needed to validate these findings.
目的:嗜瘤细胞癌(OCA)因其独特的特征而被重新分类为滤泡性甲状腺癌。由于其罕见性,导致对OCA与癌细胞性腺瘤(OA)鉴别的研究有限。本研究旨在比较OCA和OA的临床病理和术前特征,并评价超声和细胞学检查的有效性。方法:我们对2011年至2024年间接受甲状腺手术的83例患者(23例OCA, 60例OA)进行了回顾性研究。我们回顾了临床、超声、细胞学和组织病理学资料来评估诊断表现。结果:超声(4.2±1.7 cm vs. 2.7±1.4 cm, P < 0.001)和病理(3.8±1.7 cm vs. 2.3±1.4 cm, P < 0.001)显示OCA患者肿瘤大于OA。K-TIRADS(韩国甲状腺成像报告和数据系统)不能有效区分OCA和OA;然而,ACR TI-RADS(美国放射学会甲状腺影像学报告和数据系统)将更多的OCA病例分类为高风险组(17.4%比1.7%,P = 0.016)。小梁形成和结节内血管在OCA中更为常见(17.4% vs. 1.7%, P = 0.019;65.2% vs. 33.3%, P = 0.049)。细胞学上,87%的oca被归类为滤泡性肿瘤,而20%的oa被归类为滤泡性肿瘤。结论:预测嗜瘤细胞肿瘤的恶性是具有挑战性的。较大的肿瘤大小、较高的ACR TI-RADS评分和小梁形成是OCA的潜在指标。Bethesda IV的细胞学亚分类表明,滤泡性肿瘤比嗜酸细胞性肿瘤具有更高的恶性风险。需要多中心研究来验证这些发现。
{"title":"Differentiating oncocytic carcinoma from oncocytic adenoma: a comprehensive evaluation of preoperative characteristics and diagnostic approaches in a retrospective cohort study.","authors":"Eunji Kim, Jun Hyun Park, Ji-Young Park, Sang-Woo Lee, Jin Hyang Jung","doi":"10.4174/astr.2025.109.2.105","DOIUrl":"10.4174/astr.2025.109.2.105","url":null,"abstract":"<p><strong>Purpose: </strong>Oncocytic carcinoma (OCA) has been reclassified from follicular thyroid carcinoma due to its unique features. Its rarity has resulted in limited studies on differentiating OCA from oncocytic adenoma (OA). This study aimed to compare the clinicopathologic and preoperative features of OCA and OA and evaluate the effectiveness of ultrasonography and cytology.</p><p><strong>Methods: </strong>We conducted a retrospective study involving 83 patients (23 with OCA and 60 with OA) who underwent thyroid surgery between 2011 and 2024. We reviewed clinical, ultrasonographic, cytologic, and histopathologic data to assess diagnostic performance.</p><p><strong>Results: </strong>OCA cases had larger tumors than OA in both sonographic (4.2 ± 1.7 cm <i>vs.</i> 2.7 ± 1.4 cm, P < 0.001) and pathologic measurements (3.8 ± 1.7 cm <i>vs.</i> 2.3 ± 1.4 cm, P < 0.001). K-TIRADS (the Korean Thyroid Imaging Reporting and Data System) did not effectively distinguish OCA from OA; however, ACR TI-RADS (the American College of Radiology Thyroid Imaging Reporting and Data System) categorized more OCA cases into higher-risk groups (17.4% <i>vs.</i> 1.7%, P = 0.016). Trabecular formation and intranodular vascularity were more frequent in OCA (17.4% <i>vs.</i> 1.7%, P = 0.019; 65.2% <i>vs.</i> 33.3%, P = 0.049). Cytologically, 87% of OCAs were classified as follicular neoplasms compared to 20% of OAs.</p><p><strong>Conclusion: </strong>Predicting malignancy in oncocytic neoplasms is challenging. Larger tumor size, higher ACR TI-RADS scores, and trabecular formation are potential indicators for OCA. Cytologic subcategorization within Bethesda IV suggests follicular neoplasms carry a higher malignancy risk than oncocytic neoplasms. Multicenter studies are needed to validate these findings.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"105-112"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-30DOI: 10.4174/astr.2025.109.2.71
HyeJeong Jeong, Hee Joon Kim, Soo Yeun Lim, Hyun Jeong Jeon, So Jeong Yoon, Hongbeom Kim, In Woong Han, Jin Seok Heo, Sang Hyun Shin
Purpose: Hilar cholangiocarcinoma is known for its poor prognosis due to late diagnosis. To achieve long-term survival, curative resection often is necessary. However, after surgical resection, the 5-year survival rates vary from 14% to 48%. The aim of this study is to evaluate the prognostic factors for long-term survival in hilar cholangiocarcinoma.
Methods: Patients who underwent curative resection for hilar cholangiocarcinoma at Samsung Medical Center from January 2000 to December 2020 were included. Demographics, surgical and oncological outcomes, short-term complications, recurrence, pathologic results, and survival were analyzed. Prognostic factors were analyzed with Cox proportional hazards models.
Results: A total of 449 patients diagnosed with hilar cholangiocarcinoma who underwent intent-to-treat resection at Samsung Medical Center from 2000 to 2020 were included in this study. The median disease-free survival was 19 months, and the median survival was 40 months. One-, 3-, and 5-year survival rates were 82.8%, 53.7%, and 35.8%, respectively.
Conclusion: The 5-year survival rate of patients with hilar cholangiocarcinoma was 35.8% at Samsung Medical Center. Median survival was 40 months. N2 stage and tumor biology were factors affecting 5-year survival.
{"title":"Five-year survival of patients with hilar cholangiocarcinoma: a single-center retrospective study.","authors":"HyeJeong Jeong, Hee Joon Kim, Soo Yeun Lim, Hyun Jeong Jeon, So Jeong Yoon, Hongbeom Kim, In Woong Han, Jin Seok Heo, Sang Hyun Shin","doi":"10.4174/astr.2025.109.2.71","DOIUrl":"10.4174/astr.2025.109.2.71","url":null,"abstract":"<p><strong>Purpose: </strong>Hilar cholangiocarcinoma is known for its poor prognosis due to late diagnosis. To achieve long-term survival, curative resection often is necessary. However, after surgical resection, the 5-year survival rates vary from 14% to 48%. The aim of this study is to evaluate the prognostic factors for long-term survival in hilar cholangiocarcinoma.</p><p><strong>Methods: </strong>Patients who underwent curative resection for hilar cholangiocarcinoma at Samsung Medical Center from January 2000 to December 2020 were included. Demographics, surgical and oncological outcomes, short-term complications, recurrence, pathologic results, and survival were analyzed. Prognostic factors were analyzed with Cox proportional hazards models.</p><p><strong>Results: </strong>A total of 449 patients diagnosed with hilar cholangiocarcinoma who underwent intent-to-treat resection at Samsung Medical Center from 2000 to 2020 were included in this study. The median disease-free survival was 19 months, and the median survival was 40 months. One-, 3-, and 5-year survival rates were 82.8%, 53.7%, and 35.8%, respectively.</p><p><strong>Conclusion: </strong>The 5-year survival rate of patients with hilar cholangiocarcinoma was 35.8% at Samsung Medical Center. Median survival was 40 months. N2 stage and tumor biology were factors affecting 5-year survival.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"71-80"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-30DOI: 10.4174/astr.2025.109.2.89
Chang Hyun Kim, Jae Kyun Ju, Jaram Lee, Hyeung-Min Park, Soo Young Lee, Hyeong Rok Kim, Young Eun Joo, Sung Bum Cho
Purpose: The selection of primary tumor resection (PTR) vs. self-expanding metallic stents (SEMS) in obstructive unresectable stage IV colorectal cancer (CRC) is critical, profoundly impacting patient outcome. This study evaluates the influence of PTR and SEMS on overall survival (OS) in conjunction with chemotherapy.
Methods: The analysis included 137 patients with obstructive, unresectable stage IV CRC who underwent PTR or attempted SEMS placement. The primary objective was to assess the OS of patients, specifically examining how PTR and SEMS interventions influence these survival outcomes.
Results: In a cohort of 137 patients with obstructive, unresectable stage IV CRC, 30 initially opted for PTR, while stent placement was attempted in 107 cases. Following 14 stent failures, which resulted in 8 diversions and 6 additional PTR interventions, exclusions due to elective surgeries led to a final analysis of 36 PTR and 72 SEMS cases. Cox regression analysis identified no significant survival advantage between PTR and SEMS interventions (hazard ratio [HR], 0.848; 95% confidence interval [CI], 0.555-1.298; P = 0.449). Critical findings highlighted that the absence of chemotherapy markedly reduced survival prospects (HR, 1.963; 95% CI, 1.200-3.211; P = 0.007). These insights were substantiated through propensity score matching.
Conclusion: The comparative analysis reveals that neither PTR nor SEMS offers a definitive survival advantage in managing obstructive, unresectable stage IV CRC. However, the necessity for subsequent invasive interventions is notably lower in the PTR group.
{"title":"Primary tumor resection <i>vs.</i> self-expandable metallic stent in unresectable obstructive stage IV colorectal cancer: a comparative outcome study.","authors":"Chang Hyun Kim, Jae Kyun Ju, Jaram Lee, Hyeung-Min Park, Soo Young Lee, Hyeong Rok Kim, Young Eun Joo, Sung Bum Cho","doi":"10.4174/astr.2025.109.2.89","DOIUrl":"10.4174/astr.2025.109.2.89","url":null,"abstract":"<p><strong>Purpose: </strong>The selection of primary tumor resection (PTR) <i>vs.</i> self-expanding metallic stents (SEMS) in obstructive unresectable stage IV colorectal cancer (CRC) is critical, profoundly impacting patient outcome. This study evaluates the influence of PTR and SEMS on overall survival (OS) in conjunction with chemotherapy.</p><p><strong>Methods: </strong>The analysis included 137 patients with obstructive, unresectable stage IV CRC who underwent PTR or attempted SEMS placement. The primary objective was to assess the OS of patients, specifically examining how PTR and SEMS interventions influence these survival outcomes.</p><p><strong>Results: </strong>In a cohort of 137 patients with obstructive, unresectable stage IV CRC, 30 initially opted for PTR, while stent placement was attempted in 107 cases. Following 14 stent failures, which resulted in 8 diversions and 6 additional PTR interventions, exclusions due to elective surgeries led to a final analysis of 36 PTR and 72 SEMS cases. Cox regression analysis identified no significant survival advantage between PTR and SEMS interventions (hazard ratio [HR], 0.848; 95% confidence interval [CI], 0.555-1.298; P = 0.449). Critical findings highlighted that the absence of chemotherapy markedly reduced survival prospects (HR, 1.963; 95% CI, 1.200-3.211; P = 0.007). These insights were substantiated through propensity score matching.</p><p><strong>Conclusion: </strong>The comparative analysis reveals that neither PTR nor SEMS offers a definitive survival advantage in managing obstructive, unresectable stage IV CRC. However, the necessity for subsequent invasive interventions is notably lower in the PTR group.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"89-97"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-30DOI: 10.4174/astr.2025.109.2.98
Tae-Han Kim, Sang-Ho Jeong, Young-Joon Lee, Dong-Hwan Kim, Han-Gil Kim, Jae-Myung Kim, Jin-Kyu Cho, Seung-Jin Kwag, Ju-Yeon Kim, Young-Tae Ju, Chi-Young Jeong, Ji-Ho Park
Purpose: This study investigates risk factors for recurrence in patients who underwent laparoscopic primary closure (PC) for pyloroduodenal ulcer perforation (PUP).
Methods: We retrospectively analyzed data from patients who underwent laparoscopic PC with or without highly selective vagotomy (HSV) for PUP at a tertiary hospital from 2010 to 2019. Demographics, surgical outcomes, proton pump inhibitor (PPI) use, Helicobacter pylori status, and endoscopic findings were reviewed. Long-term (5 years) endoscopic and clinical outcomes regarding ulcer and perforation recurrence, were collected.
Results: A total of 139 patients were included in the analysis. Of these, 109 (78.4%) were male, and 76 (54.7%) were current smokers. Ninety-five patients (68.3%) underwent PC only, while 44 (31.7%) received PC + HSV. During the follow-up period, ulcer recurrence was observed in 19 patients (13.7%) and perforation recurrence in 9 (6.5%). In Cox proportional analysis for ulcer recurrence, smoking (hazard ratio [HR], 6.476; 95% confidence interval [CI], 1.834-22.873; P = 0.004) and older age (HR, 1.049; 95% CI, 1.012-1.088; P = 0.009) were identified as significant factors. For peptic ulcer perforation recurrence, smoking (HR, 19.129; 95% CI, 2.048-178.702; P = 0.010) and older age (HR, 1.062; 95% CI, 1.009-1.118; P = 0.021) were significant. No significant associations were found between sex, duration of PPI therapy, H. pylori eradication success, or surgery type and the risk of either ulcer or perforation recurrence.
Conclusion: Smoking and age are important factors for recurrence following laparoscopic PC for PUP. These findings emphasize the need for smoking cessation and close postoperative monitoring.
{"title":"Impact of smoking and age on long-term recurrence after laparoscopic primary closure for duodenal ulcer perforation: a 5-year observational study.","authors":"Tae-Han Kim, Sang-Ho Jeong, Young-Joon Lee, Dong-Hwan Kim, Han-Gil Kim, Jae-Myung Kim, Jin-Kyu Cho, Seung-Jin Kwag, Ju-Yeon Kim, Young-Tae Ju, Chi-Young Jeong, Ji-Ho Park","doi":"10.4174/astr.2025.109.2.98","DOIUrl":"10.4174/astr.2025.109.2.98","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates risk factors for recurrence in patients who underwent laparoscopic primary closure (PC) for pyloroduodenal ulcer perforation (PUP).</p><p><strong>Methods: </strong>We retrospectively analyzed data from patients who underwent laparoscopic PC with or without highly selective vagotomy (HSV) for PUP at a tertiary hospital from 2010 to 2019. Demographics, surgical outcomes, proton pump inhibitor (PPI) use, <i>Helicobacter pylori</i> status, and endoscopic findings were reviewed. Long-term (5 years) endoscopic and clinical outcomes regarding ulcer and perforation recurrence, were collected.</p><p><strong>Results: </strong>A total of 139 patients were included in the analysis. Of these, 109 (78.4%) were male, and 76 (54.7%) were current smokers. Ninety-five patients (68.3%) underwent PC only, while 44 (31.7%) received PC + HSV. During the follow-up period, ulcer recurrence was observed in 19 patients (13.7%) and perforation recurrence in 9 (6.5%). In Cox proportional analysis for ulcer recurrence, smoking (hazard ratio [HR], 6.476; 95% confidence interval [CI], 1.834-22.873; P = 0.004) and older age (HR, 1.049; 95% CI, 1.012-1.088; P = 0.009) were identified as significant factors. For peptic ulcer perforation recurrence, smoking (HR, 19.129; 95% CI, 2.048-178.702; P = 0.010) and older age (HR, 1.062; 95% CI, 1.009-1.118; P = 0.021) were significant. No significant associations were found between sex, duration of PPI therapy, <i>H. pylori</i> eradication success, or surgery type and the risk of either ulcer or perforation recurrence.</p><p><strong>Conclusion: </strong>Smoking and age are important factors for recurrence following laparoscopic PC for PUP. These findings emphasize the need for smoking cessation and close postoperative monitoring.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"98-104"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-30DOI: 10.4174/astr.2025.109.2.113
Young Min Song, Kyung Su Han, Byung Chang Kim, Chang Won Hong, Bun Kim, Dae Kyung Sohn
Purpose: This study introduced adenomas per polypectomy (APP) as a novel metric for evaluating the progression of lesion discrimination skills among colonoscopy trainees.
Methods: This retrospective study was conducted at the National Cancer Center, Korea between March 2020 and February 2023. Nine colorectal surgeons who completed a structured 1-year colonoscopy training program were included, and their performance was compared with that of 5 expert endoscopists. APP was defined as the number of histologically confirmed adenomas among the total number of polypectomies performed. The APPs were calculated serially to assess changes from the beginning to the end of the training.
Results: A total of 8,072 colonoscopies were performed by 9 trainees and 11,687 by 5 experts. The average APP of the 9 trainees was 67.0%, which was significantly different from the 73.9% APP of the experts (P < 0.001). The APP progression of trainees exhibited 3 phases: phase 1 (<200 cases) showed increasing polyp detection and APP; phase 2 (200-500 cases) displayed a sharp rise in the number of polypectomies but a decline in APP; and phase 3 (>500 cases) demonstrated a decrease in the number of polypectomies with a moderate rise in APP. However, even in phase 3, the trainees' APP remained significantly lower than that of the experts (69.9% vs. 73.9%, P = 0.027).
Conclusion: APP, a measure of visual adenoma discrimination ability, undergoes 3 stages of progression during colonoscopy training. This progression suggests that the APP may serve as an additional metric for assessing the effectiveness of colonoscopy training.
目的:本研究引入腺瘤息肉切除术(APP)作为评估结肠镜检查学员病变识别技能进展的新指标。方法:这项回顾性研究于2020年3月至2023年2月在韩国国家癌症中心进行。9名结直肠外科医生完成了为期1年的结肠镜检查培训计划,并将他们的表现与5名内窥镜专家的表现进行比较。APP定义为病理证实的腺瘤在息肉切除术总数中的数量。连续计算app,以评估从训练开始到结束的变化。结果:9名学员完成结肠镜检查8072例,5名专家完成结肠镜检查11687例。9名学员的平均APP为67.0%,与专家的73.9%有显著差异(P < 0.001)。受训人员的APP进展分为3个阶段:第1阶段(500例)显示息肉数量减少,APP适度上升。然而,即使在第3阶段,受训人员的APP仍然明显低于专家(69.9% vs. 73.9%, P = 0.027)。结论:APP在结肠镜检查训练过程中可分为3个阶段,是衡量视觉腺瘤识别能力的指标。这一进展表明APP可以作为评估结肠镜检查训练有效性的额外指标。
{"title":"Adenoma per polypectomy as a training metric in colonoscopy: a retrospective analysis of trainee progression compared to expert performance.","authors":"Young Min Song, Kyung Su Han, Byung Chang Kim, Chang Won Hong, Bun Kim, Dae Kyung Sohn","doi":"10.4174/astr.2025.109.2.113","DOIUrl":"10.4174/astr.2025.109.2.113","url":null,"abstract":"<p><strong>Purpose: </strong>This study introduced adenomas per polypectomy (APP) as a novel metric for evaluating the progression of lesion discrimination skills among colonoscopy trainees.</p><p><strong>Methods: </strong>This retrospective study was conducted at the National Cancer Center, Korea between March 2020 and February 2023. Nine colorectal surgeons who completed a structured 1-year colonoscopy training program were included, and their performance was compared with that of 5 expert endoscopists. APP was defined as the number of histologically confirmed adenomas among the total number of polypectomies performed. The APPs were calculated serially to assess changes from the beginning to the end of the training.</p><p><strong>Results: </strong>A total of 8,072 colonoscopies were performed by 9 trainees and 11,687 by 5 experts. The average APP of the 9 trainees was 67.0%, which was significantly different from the 73.9% APP of the experts (P < 0.001). The APP progression of trainees exhibited 3 phases: phase 1 (<200 cases) showed increasing polyp detection and APP; phase 2 (200-500 cases) displayed a sharp rise in the number of polypectomies but a decline in APP; and phase 3 (>500 cases) demonstrated a decrease in the number of polypectomies with a moderate rise in APP. However, even in phase 3, the trainees' APP remained significantly lower than that of the experts (69.9% <i>vs.</i> 73.9%, P = 0.027).</p><p><strong>Conclusion: </strong>APP, a measure of visual adenoma discrimination ability, undergoes 3 stages of progression during colonoscopy training. This progression suggests that the APP may serve as an additional metric for assessing the effectiveness of colonoscopy training.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 2","pages":"113-119"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01Epub Date: 2025-07-02DOI: 10.4174/astr.2025.109.1.27
Na Reum Kim, Gi Hong Choi, Jin Sub Choi, Dai Hoon Han
Purpose: Given the widening of the donor pool to include patients with steatosis, small-for-size grafts, and older patients, this study examined the effect of age on liver volumetric regeneration after a donor right hepatectomy.
Methods: We enrolled 33 older (≥55 years) and 277 younger (<30 years) donors who underwent donor right hepatectomy between March 2012 and December 2022. After propensity score-matched analysis, the perioperative surgical outcomes and growth rates of the remnant liver in 63 younger and 32 older donors were compared. Liver regeneration was assessed using CT volumetry for up to 6 months after surgery. Poor liver regeneration was defined as restoration of less than 80% of the original liver volume. The risk factors for poor liver regeneration were analyzed using a binary logistic regression model.
Results: The mean age of older and younger donors was 58.0 and 24.3 years, respectively. Despite comparable preoperative factors, older donors showed significantly lower regeneration rates at all observed time points (1 month: 75.5% vs. 82.3%, P = 0.001; 3 months: 80.4% vs. 90.5%, P < 0.001; and 6 months: 87.9% vs. 95.8, P = 0.006, compared to total liver volume). A large total liver volume and older age were identified as risk factors for poor liver regeneration.
Conclusion: Older donors showed a reduced capacity for liver regeneration. This finding suggests the need for the development of more conservative criteria for residual liver volume in older donors than for younger donors to ensure donor safety.
目的:考虑到供体池的扩大,包括脂肪变性患者、小尺寸移植物患者和老年患者,本研究探讨了年龄对供体右肝切除术后肝脏体积再生的影响。方法:我们招募了33名老年人(≥55岁)和277名年轻人(结果:老年人和年轻人的平均年龄分别为58.0岁和24.3岁)。尽管术前因素具有可比性,但老年供体在所有观察时间点的再生率都明显较低(1个月:75.5% vs. 82.3%, P = 0.001;3个月:80.4% vs. 90.5%, P < 0.001;6个月:87.9% vs. 95.8, P = 0.006)。肝总容量大和年龄大被认为是肝再生不良的危险因素。结论:老年供体肝脏再生能力下降。这一发现表明,为确保供体安全,老年供体的剩余肝容量需要制定比年轻供体更保守的标准。
{"title":"Age-related impact on liver regeneration in older donors after living-donor right hepatectomy: a propensity score-matched cohort study.","authors":"Na Reum Kim, Gi Hong Choi, Jin Sub Choi, Dai Hoon Han","doi":"10.4174/astr.2025.109.1.27","DOIUrl":"10.4174/astr.2025.109.1.27","url":null,"abstract":"<p><strong>Purpose: </strong>Given the widening of the donor pool to include patients with steatosis, small-for-size grafts, and older patients, this study examined the effect of age on liver volumetric regeneration after a donor right hepatectomy.</p><p><strong>Methods: </strong>We enrolled 33 older (≥55 years) and 277 younger (<30 years) donors who underwent donor right hepatectomy between March 2012 and December 2022. After propensity score-matched analysis, the perioperative surgical outcomes and growth rates of the remnant liver in 63 younger and 32 older donors were compared. Liver regeneration was assessed using CT volumetry for up to 6 months after surgery. Poor liver regeneration was defined as restoration of less than 80% of the original liver volume. The risk factors for poor liver regeneration were analyzed using a binary logistic regression model.</p><p><strong>Results: </strong>The mean age of older and younger donors was 58.0 and 24.3 years, respectively. Despite comparable preoperative factors, older donors showed significantly lower regeneration rates at all observed time points (1 month: 75.5% <i>vs.</i> 82.3%, P = 0.001; 3 months: 80.4% <i>vs.</i> 90.5%, P < 0.001; and 6 months: 87.9% <i>vs.</i> 95.8, P = 0.006, compared to total liver volume). A large total liver volume and older age were identified as risk factors for poor liver regeneration.</p><p><strong>Conclusion: </strong>Older donors showed a reduced capacity for liver regeneration. This finding suggests the need for the development of more conservative criteria for residual liver volume in older donors than for younger donors to ensure donor safety.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 1","pages":"27-34"},"PeriodicalIF":1.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01Epub Date: 2025-07-02DOI: 10.4174/astr.2025.109.1.15
Jae Hwan Jeong, Seung Soo Hong, Sung Hyun Kim, Ho Kyoung Hwang, Kyung Sik Kim, Chang Moo Kang
Purpose: The oncologic benefits of adjuvant chemotherapy for resected ampulla of Vater cancer (AoVCa) remain contentious. This study aimed to evaluate the long-term oncologic effects of postoperative adjuvant chemotherapy (PACT) in patients who underwent radical surgery for AoVCa.
Methods: From 2005 to 2019, clinical and pathological data of 306 AoVCa patients who underwent pancreatoduodenectomy were retrospectively reviewed. Patients were divided into the PACT (+) and PACT (-) groups. Propensity score matching (PSM) was conducted to adjust for clinical factors.
Results: The PACT (+) group (n = 124) and PACT (-) group (n = 182) showed significant differences in cancer stage, lymph node metastasis, perineural invasion, lymphovascular invasion, and cancer differentiation. Lower overall survival (OS) (P < 0.001) and disease-free survival (DFS) (P < 0.001) were observed in the PACT (+) group. After PSM, no significant differences in OS or DFS were found between the groups. Multivariate analysis identified lymph node metastasis and perineural invasion as significant prognostic factors, while PACT did not significantly impact long-term survival. Paradoxically, PACT was associated with worse outcomes in patients with favorable prognostic factors.
Conclusion: This study suggests that PACT does not provide a clear oncologic benefit for resected AoVCa patients and may even be detrimental for those with favorable prognostic factors. There is an urgent need to develop effective anticancer treatments and consider tailored therapeutic approaches based on individual patient profiles. Future research should focus on long-term follow-up and the integration of precision medicine to improve outcomes for AoVCa patients.
{"title":"Long-term oncologic benefit of postoperative chemotherapy in the resected ampulla of Vater cancer: hope or hype? A propensity score matching analysis.","authors":"Jae Hwan Jeong, Seung Soo Hong, Sung Hyun Kim, Ho Kyoung Hwang, Kyung Sik Kim, Chang Moo Kang","doi":"10.4174/astr.2025.109.1.15","DOIUrl":"10.4174/astr.2025.109.1.15","url":null,"abstract":"<p><strong>Purpose: </strong>The oncologic benefits of adjuvant chemotherapy for resected ampulla of Vater cancer (AoVCa) remain contentious. This study aimed to evaluate the long-term oncologic effects of postoperative adjuvant chemotherapy (PACT) in patients who underwent radical surgery for AoVCa.</p><p><strong>Methods: </strong>From 2005 to 2019, clinical and pathological data of 306 AoVCa patients who underwent pancreatoduodenectomy were retrospectively reviewed. Patients were divided into the PACT (+) and PACT (-) groups. Propensity score matching (PSM) was conducted to adjust for clinical factors.</p><p><strong>Results: </strong>The PACT (+) group (n = 124) and PACT (-) group (n = 182) showed significant differences in cancer stage, lymph node metastasis, perineural invasion, lymphovascular invasion, and cancer differentiation. Lower overall survival (OS) (P < 0.001) and disease-free survival (DFS) (P < 0.001) were observed in the PACT (+) group. After PSM, no significant differences in OS or DFS were found between the groups. Multivariate analysis identified lymph node metastasis and perineural invasion as significant prognostic factors, while PACT did not significantly impact long-term survival. Paradoxically, PACT was associated with worse outcomes in patients with favorable prognostic factors.</p><p><strong>Conclusion: </strong>This study suggests that PACT does not provide a clear oncologic benefit for resected AoVCa patients and may even be detrimental for those with favorable prognostic factors. There is an urgent need to develop effective anticancer treatments and consider tailored therapeutic approaches based on individual patient profiles. Future research should focus on long-term follow-up and the integration of precision medicine to improve outcomes for AoVCa patients.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"109 1","pages":"15-26"},"PeriodicalIF":1.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}